- Home
- RMM vs XOMA Comparison
RMM vs XOMA Comparison
Compare RMM & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- XOMA
- Stock Information
- Founded
- RMM 2019
- XOMA 1981
- Country
- RMM United States
- XOMA United States
- Employees
- RMM N/A
- XOMA N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- RMM Finance
- XOMA Health Care
- Exchange
- RMM Nasdaq
- XOMA Nasdaq
- Market Cap
- RMM 309.7M
- XOMA 320.8M
- IPO Year
- RMM N/A
- XOMA N/A
- Fundamental
- Price
- RMM $15.91
- XOMA $28.59
- Analyst Decision
- RMM
- XOMA Strong Buy
- Analyst Count
- RMM 0
- XOMA 2
- Target Price
- RMM N/A
- XOMA $78.50
- AVG Volume (30 Days)
- RMM 66.5K
- XOMA 18.9K
- Earning Date
- RMM 01-01-0001
- XOMA 11-05-2024
- Dividend Yield
- RMM 7.33%
- XOMA N/A
- EPS Growth
- RMM N/A
- XOMA N/A
- EPS
- RMM 0.96
- XOMA N/A
- Revenue
- RMM N/A
- XOMA $15,239,000.00
- Revenue This Year
- RMM N/A
- XOMA $456.45
- Revenue Next Year
- RMM N/A
- XOMA $29.84
- P/E Ratio
- RMM $15.55
- XOMA N/A
- Revenue Growth
- RMM N/A
- XOMA 277.95
- 52 Week Low
- RMM $12.32
- XOMA $14.27
- 52 Week High
- RMM $16.10
- XOMA $30.50
- Technical
- Relative Strength Index (RSI)
- RMM 50.91
- XOMA 53.55
- Support Level
- RMM $15.70
- XOMA $28.66
- Resistance Level
- RMM $16.07
- XOMA $30.50
- Average True Range (ATR)
- RMM 0.20
- XOMA 1.07
- MACD
- RMM -0.02
- XOMA 0.21
- Stochastic Oscillator
- RMM 31.34
- XOMA 55.56
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.